— Know what they know.
Not Investment Advice

GLUE NASDAQ

Monte Rosa Therapeutics, Inc.
1W: +1.1% 1M: -10.0% 3M: -0.5% YTD: +23.3% 1Y: +353.9% 3Y: +237.8%
$18.81
-0.07 (-0.37%)
 
Weekly Expected Move ±7.0%
$16 $17 $18 $19 $21
NASDAQ · Healthcare · Biotechnology · Alpha Radar Neutral · Power 42 · $1.2B mcap · 42M float · 2.37% daily turnover · Short 77% of daily vol

Balance Sheet Trends

Total Assets
$449M +2.3% ▲
5Y CAGR: +55.5%
Total Liabilities
$216M -0.1% ▼
5Y CAGR: +17.1%
Shareholders Equity
$233M +4.5% ▲
Cash & Investments
$377M +1.3% ▲
5Y CAGR: +55.3%
Total Debt
$39M -8.3% ▼
5Y CAGR: -10.4%
Net Debt
-$91M +50.0% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$346M$55M$128M$224M$130M
Short-Term Investments$0$208M$104M$148M$247M
Cash & ST Investments$346M$263M$232M$372M$377M
Net Receivables$0$8M$505K$173K$5M
Inventory$0$0$0$0$0
Other Current Assets$0$5M$3M$5M$11M
Total Current Assets$349M$276M$236M$377M$393M
Property, Plant & Equip.$12M$62M$63M$56M$50M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$5M$0$0$0$0
Other Non-Current Assets$0$5M$5M$5M$5M
Total Non-Current Assets$18M$67M$68M$61M$55M
Total Assets$366M$342M$304M$439M$449M
— Liabilities —
Accounts Payable$7M$8M$11M$17M$4M
Short-Term Debt$0$0$0$0$4M
Deferred Revenue$0$0$18M$117M$30M
Other Current Liabilities$840K$11M$9M$12M$27M
Total Current Liabilities$17M$26M$47M$157M$64M
Long-Term Debt$0$0$0$0$35M
Other Non-Current Liab.$2M$2M$3M$4M$5M
Total Non-Current Liabilities$2M$45M$78M$59M$151M
Total Liabilities$19M$71M$125M$216M$216M
— Equity —
Common Stock$5K$5K$5K$6K$7K
Retained Earnings-$122M-$231M-$366M-$439M-$477M
Accumulated OCI-$2M-$2M-$3M-$3M-$4M
Total Stockholders Equity$348M$271M$179M$223M$233M
Total Liabilities & Equity$366M$342M$304M$439M$449M
— Key Metrics —
Total Debt$0$47M$46M$43M$39M
Net Debt-$346M-$8M-$82M-$182M-$91M
Total Investments$5M$208M$104M$148M$247M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms